Table 4: AEs occurring in ³5 percent of the total patient population
|
|
Alefacept SC |
Alefacept IM |
Total |
|
Headache |
8 (17) |
3 (7) |
10 (20) |
|
Upper respiratory tract infection |
4 (8) |
2 (5) |
6 (12) |
|
Pharyngolaryngeal pain |
3 (6) |
2 (5) |
5 (10) |
|
Back pain |
2 (4) |
2 (5) |
4 (8) |
|
Lymphadenopathy |
3 (6) |
1 (2) |
4 (8) |
|
Migraine |
0 (0) |
4 (9) |
4 (8) |
|
Nasal congestion
|
2 (4) |
2 (5) |
4 (8) |
|
Dizziness |
3 (6) |
0 (0) |
3 (6) |
|
Dyspepsia |
1 (2) |
2 (5) |
3 (6) |
Muscle cramp |
1 (2) |
2 (5) |
3 (6) |
|
Nausea |
2 (4) |
1 (2) |
3 (6) |
|
Rhinorrhea |
1 (2) |
2 (5) |
3 (6) |
|
Tension headache |
2 (4) |
1 (2) |
3 (6) |
AE, adverse event; IM, intramuscular; SC, subcutaneous.
.